Bachem Holding AG Stock – Fundamental Analysis

Price
82.30
10/14/2026
Jun 1998
Oct 2026

Fundamental Data & Ratios (Balance sheet update: 3/22/2026)

Balance Sheet Total Assets 2,108,720,000.00 ROE 69.16 %
Balance Sheet Total Equity 1,458,320,000.00 ROA 7.06 %
Cashflow Capital Expenditures -319,564,000.00 P/FCF -127.99
Cashflow Free Cash Flow -48,202,000.00 – –
Cashflow Operating Cash Flow 271,362,000.00 P/CF 22.73
Income Earnings per Share (diluted) 1.98 Div. Yield 1.03 %
Income Net Income 148,793,000.00 P/E 41.57
Income Shares Outstanding 74,961,800.00 P/B 4.23
Income Total Revenue 695,070,000.00 P/S 8.88

Ratios calculated on: 10/14/2026

Company Description

Bachem Holding AG, a technology-based biochemicals company, provides services to the pharmaceutical and biotechnology industries primarily in Switzerland, the United States, Germany, Ireland, the United Kingdom, Austria, Japan, and internationally. It develops and manufactures peptide and oligonucleotides as active pharmaceutical ingredients (APIs), as well as biochemicals for research purposes. The company offers research products, which include peptides, amino acid derivatives, and biochemicals for peptide research; and custom synthesis services. It also provides API products comprising generic APIs used in the fields of cancer, diabetes, obesity, fertility, and others; and peptides for new chemical entities. In addition, the company offers oligonucleotide-based APIs, as well as customer support services. Bachem Holding AG was founded in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG is a subsidiary of Ingro Finanz AG.

Advanced Analysis Features

Additional comparison and history views are available after login.

Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.bachem.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown. Learn more